UTHR240816C160000
- 78.50
- 0.000.00%
United Therapeutics Newsroom
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 5 years by 20.86% on an annualized basis producing an average annual return of 33.79%. Currently, United Therapeutics has
Is Now The Time To Put United Therapeutics (NASDAQ:UTHR) On Your Watchlist?
Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $350
Wells Fargo analyst Tiago Fauth maintains $United Therapeutics(UTHR.US)$ with a buy rating, and maintains the target price at $350.According to TipRanks data, the analyst has a success rate of 38.8%
Wells Fargo Sticks to Its Buy Rating for United Therapeutics (UTHR)
Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $344
Leerink Partners analyst Roanna Ruiz maintains $United Therapeutics(UTHR.US)$ with a buy rating, and adjusts the target price from $338 to $344.According to TipRanks data, the analyst has a success
United Therapeutics Insider Sold Shares Worth $2,355,544, According to a Recent SEC Filing
Martine A Rothblatt, Director, Chairperson & CEO, on July 15, 2024, sold 7,200 shares in United Therapeutics (UTHR) for $2,355,544. Following the Form 4 filing with the SEC, Rothblatt has control
Why United Therapeutics (UTHR) Is a Top Growth Stock for the Long-Term
Growth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company.
Express News | United Therapeutics Corp : Leerink Partners Raises Target Price to $344 From $338
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $28,000 Today
United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 20 years by 9.58% on an annualized basis producing an average annual return of 18.13%. Currently, United Therapeutics has
5 High ROE Stocks to Buy as Low Inflation Fuels Rate Cut Hopes
Is United Therapeutics (UTHR) a Solid Growth Stock? 3 Reasons to Think "Yes"
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
Two factors often determine stock prices in the long run: earnings and interest rates.
Express News | United Therapeutics Corp : Morgan Stanley Raises Target Price to $321 From $310
Express News | United Therapeutics Corp : Morgan Stanley Cuts to Equal-Weight From Overweight
TD Cowen Adjusts Price Target on United Therapeutics to $350 From $270, Maintains Buy Rating
United Therapeutics (UTHR) has an average outperform rating and price target range of $221 to $400, according to analysts polled by Capital IQ.Price: 326.49, Change: -2.76, Percent Change: -0.84
We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to
United Therapeutics Is Maintained at Buy by TD Cowen
United Therapeutics Is Maintained at Buy by TD
TD Cowen Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $350
TD Cowen analyst Joseph Thome maintains $United Therapeutics(UTHR.US)$ with a buy rating, and maintains the target price at $350.According to TipRanks data, the analyst has a success rate of 40.0%
United Therapeutics Price Target Raised to $321.00/Share From $310.00 by Morgan Stanley
United Therapeutics Price Target Raised to $321.00/Share From $310.00 by Morgan